

AML1 (Phospho-Ser435) Antibody
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP52566

Specification

AML1 (Phospho-Ser435) Antibody - Product Information

Application	WB
Primary Accession	O01196
Host	Rabbit
Clonality	Polyclonal
Calculated MW	48737

AML1 (Phospho-Ser435) Antibody - Additional Information

Gene ID 861

Other Names

Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, CBF-alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, PEA2-alpha B, PEBP2-alpha B, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, RUNX1, AML1, CBFA2

Dilution

WB~~1:1000

Format

Rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol.

Storage Conditions

-20°C

AML1 (Phospho-Ser435) Antibody - Protein Information

Name RUNX1

Synonyms AML1, CBFA2

Function

Forms the heterodimeric complex core-binding factor (CBF) with CBFβ. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'- TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFβ is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis (PubMed:17431401). Acts

synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter (PubMed: [10207087](http://www.uniprot.org/citations/10207087), PubMed: [14970218](http://www.uniprot.org/citations/14970218)). Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the energy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed: [17377532](http://www.uniprot.org/citations/17377532)). Positively regulates the expression of RORC in T-helper 17 cells (By similarity).

Cellular Location

Nucleus.

Tissue Location


Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood

AML1 (Phospho-Ser435) Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

AML1 (Phospho-Ser435) Antibody - Images



Western blot analysis of extracts from HepG2 cells, treated with PMA (125ng/ml, 30mins), using AML1 (Phospho-Ser435) antibody.



Western blot analysis of extracts from 293 cells (Lane 2), HeLa cells (Lane 3) and HepG2 cells (Lane 4), using AML1 (Phospho-Ser435) Antibody. The lane on the left is treated with synthesized peptide.

AML1 (Phospho-Ser435) Antibody - Background

CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation.

AML1 (Phospho-Ser435) Antibody - References

- Ahn M.-Y., et al. Submitted (SEP-1994) to the EMBL/GenBank/DDBJ databases.
- Miyoshi H., et al. Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991).
- Sacchi N., et al. Genes Chromosomes Cancer 11:226-236(1994).
- Nucifora G., et al. Blood 81:2728-2734(1993).
- Levanon D., et al. Genomics 23:425-432(1994).